Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05301608 · ClinicalTrials.gov registry record · Phase 1

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

A Phase 1 study of Healthy, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05301608: Recruiting Phase 1 study of Healthy, sponsored by Johns Hopkins University.

NCT05301608 is a Phase 1 study of Healthy that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05301608, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Psilocybin

Study Locations (1)

Maryland

  • Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-03-03
Est. Completion 2026-11-01
Phase Phase 1

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT05301608

The ClinicalTrials.gov registry entry for NCT05301608 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05301608 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT05301608 about?

NCT05301608 is a clinical study titled "Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought". This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity.

What is the current status of trial NCT05301608?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-03-03. Estimated completion is 2026-11-01.

What conditions does trial NCT05301608 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05301608?

The interventions under investigation include: Placebo (DRUG), Psilocybin (DRUG).

Who is sponsoring clinical trial NCT05301608?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05301608 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.